Nobuaki Saragai

Title: Nobuaki Saragai: Innovator in Pharmaceutical Chemistry

Introduction

Nobuaki Saragai is a notable inventor based in Amagasaki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of optically active compounds. With a total of 2 patents to his name, Saragai's work has implications for the treatment of various cardiovascular conditions.

Latest Patents

Saragai's latest patents focus on an improved process for producing optically active atenolol, a beta-adrenergic blocker used in the treatment of angina pectoris, arrhythmia, and hypertension. The process involves reacting a phenol compound with an optically active epihalohydrin to create an intermediate, optically active glycidyl ether compound. This intermediate is then reacted with isopropylamine, followed by a purification method that forms a salt of atenolol with a Bronsted's acid. This method allows for the separation of optically active atenolol with high optical purity from racemic atenolol through solid-liquid separation.

Career Highlights

Nobuaki Saragai is currently employed at Daiso Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has not only advanced the production of essential medications but has also contributed to the broader field of medicinal chemistry.

Collaborations

Throughout his career, Saragai has collaborated with esteemed colleagues such as Kazuhiro Kitaori and Yoshikazu Takehira. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Nobuaki Saragai's contributions to pharmaceutical chemistry, particularly through his patents on optically active atenolol, highlight his role as an innovator in the field. His work continues to influence the development of effective treatments for cardiovascular diseases.